Arcadia Biosciences
RKDA
15 hedge funds and large institutions have $431K invested in Arcadia Biosciences in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
172% more capital invested
Capital invested by funds: $159K → $431K (+$272K)
25% more funds holding
Funds holding: 12 → 15 (+3)
8.21% more ownership
Funds ownership: 4.27% → 12.48% (+8.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$202K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.9K |
| 3 |
VF
Virtu Financial
New York
|
+$35.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.78K |
| 5 |
JP Morgan Chase
New York
|
+$1.59K |
Top Sellers
RKDA Hedge Fund Activity: Q4 2023 in Review
15 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q4 2023, worth a combined $431K — up 172% from $159K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RKDA positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $202K.
- 15 institutional investors held Arcadia Biosciences (RKDA) as of Q4 2023, up from 12 in Q3 2023.
- Funds reported $431K of Arcadia Biosciences stock for Q4 2023, up 172% quarter-over-quarter.
- 3 funds opened new Arcadia Biosciences positions in Q4 2023 and 0 closed out, a net change of +3 holders.
- The largest Arcadia Biosciences buyer in Q4 2023 was Sabby Management, an estimated $202K added.
Based on aggregated 13F filings for Q4 2023.